CURRENT OPTIONS FOR THERAPEUTIC MANAGEMENT OF ESOPHAGEAL CANCER IN TERTIARY CARE HOSPITAL
Beulah Mariam Jacob*, Bobas Jose, Axa Mariam Babu, Amratha Johnson, Rilly Anil Mathew, and Janaki Torvi
Background and aim: The multistep process of carcinogenesis includes the stages of initiation, promotion, conversion, and progression. Clinical trials are being conducted on combined modality therapies, which include surgery alone, chemotherapy, immunotherapy, and radiation therapy. The aim of the study is to analyze and evaluate the current options for therapeutic management of oesophageal cancer dose, frequency and route of administration using WHO and NIH as reference therapy. Materials & Methods: It was a prospective observational study on Oesophageal cancer patients that was carried out in collaboration with the Department of Medical Oncology at KIMS, Hubli, Karnataka. The study was conducted for a period of 6 months from March 2022 to August 2022. A sample size of 100 people was included in the study. The study inclusion criteria selected people with esophageal cancer, people of all age, people of either sex and people with oesophageal cancer with comorbid conditions. Result: The study’s finding presented that the majority of the treatments given for esophageal patients were chemotherapy. In surgery procedures, feeding jejunostomy was mostly done. Cisplatin is given mostly as monotherapy and carboplatin + paclitaxel was given mostly as combination therapy. Conclusion: Chemotherapy emerges as the most effective treatment for esophageal cancer patients in this study. Although treatment outcomes have improved and death rates have decreased in recent years, there is still room for enhancement in the treatment plan. Despite advances in multimodal treatments, the overall prognosis for esophageal cancer remains challenging.
Keywords: Oesophageal cancer, squamous cell carcinoma, adenocarcinoma, cisplatin, carboplatin, oxaliplatin, 5-fluorouracil, paclitaxel.
[Full Text Article]